Ryan W. Jacobs, MD

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Ryan Jacobs, MD, hematologist and medical oncologist, Levine Cancer Institute, Atrium Health, discusses early responses with the novel CD19 and CD3 T-cell engager TNB-486 in relapsed/refractory follicular lymphoma according to a phase 1 study.

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.

Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.

Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.

Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.